See more : Philip Morris International Inc. (PMI.SW) Income Statement Analysis – Financial Results
Complete financial analysis of Monopar Therapeutics Inc. (MNPR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monopar Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Newell Brands Inc. (NWL) Income Statement Analysis – Financial Results
- Pettenati S.A. Industria Têxtil (PTNT4.SA) Income Statement Analysis – Financial Results
- Companhia Tecidos Santanense Ltda. (CTSA4.SA) Income Statement Analysis – Financial Results
- Marlin Technology Corporation (FINM) Income Statement Analysis – Financial Results
- Nissin Foods Holdings Co.,Ltd. (NFPDF) Income Statement Analysis – Financial Results
Monopar Therapeutics Inc. (MNPR)
About Monopar Therapeutics Inc.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 15.44M | 280.36K | 101.49K |
| General & Administrative | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Selling & Marketing | -3.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.47K | 587.08K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.50M | 0.00 | 0.00 |
| Operating Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Cost & Expenses | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.40M | 16.60M | 1.19M | 688.56K |
| Interest Income | 429.04M | 21.24K | 24.02K | 81.90K | 98.89K | 103.22K | 48.26K | 7.23K | 1.25K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.22K | 48.26K | 7.23K | 0.00 |
| Depreciation & Amortization | 8.83M | 10.54M | 9.13M | 6.51M | 4.32M | 3.33M | 2.10M | 1.19M | 688.56K |
| EBITDA | 429.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -16.55M | 8.03K | 1.25K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.83M | -10.54M | -9.13M | -6.51M | -4.32M | -3.40M | -16.60M | -1.19M | -688.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 429.04K | 21.24K | 24.02K | 204.30K | 98.89K | 31.15K | 48.26K | 8.03K | 1.25K |
| Income Before Tax | -8.40M | -10.52M | -9.10M | -6.30M | -4.22M | -3.30M | -16.55M | -1.19M | -687.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -21.24K | -24.02K | -81.90K | -98.89K | -71.62K | -2.10M | 800.00 | -688.56K |
| Net Income | -8.40M | -10.49M | -9.08M | -6.22M | -4.13M | -3.23M | -16.55M | -1.19M | -687.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| EPS Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 | -1.59 | -0.11 | -0.06 |
| Weighted Avg Shares Out | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
| Weighted Avg Shares Out (Dil) | 14.51M | 12.72M | 12.47M | 10.96M | 10.59M | 10.42M | 10.42M | 10.42M | 10.59M |
Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?
Monopar Therapeutics Skyrockets 400% on Licensing Deal
Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Source: https://incomestatements.info
Category: Stock Reports